An animal litter box includes: an upper container including a liquid passage portion having holes through which urine passes downward; a tray on which an absorbent body is disposed to absorb the urine that passes through the liquid passage portion; a lower container that supports the upper container from below and that detachably accommodates the tray; and a ventilation fan disposed in the lower container and that sends internal air in the lower container to an outside.

A composition comprising a hydrogen peroxide source and at least one salicylate. Preferably, the hydrogen peroxide source comprises hydrogen peroxide and a means for generating hydrogen peroxide.

The present invention relates to the pulmonary delivery of antibodies or antibody derivatives.

A NAB815 compound having the following formula (I), wherein: L is OA, R1 is -Dab, R2 is -Thr, R3 is -DThr, R4 is -Dab, R5 is -Dab, R6 is -DPhe, R7 is -Leu, R8 is -Abu, R9 is -Dab, R10 is -Thr, or a pharmaceutically acceptable salt thereof is provided for a use in the treatment and/or the prevention of the hemolytic-uremic syndrome.

##STR00001##

The present invention relates to a soya bean oil- and caffeine-based chemical product for use as an agrochemical for agriculture, animal husbandry and agricultural systems (pesticide/insecticide/larvicide/anti-parasitic agent), having a simple formula and production process and containing widely known organic plant ingredients.

The invention relates to antimicrobial peptides (AMPs). The invention also relates to uses, methods of treatment, pharmaceutical compositions and combinations with antimicrobial agents.

The present invention relates to a composition comprising bacteria of the Delftia genus, specifically a composition comprising Delftia tsuruhatensis as well as the bacteria itself for use in the prevention of malaria transmission and methods of using the compositions for reducing malaria and/or malaria parasite transmission.

The disclosure provides microbial compositions (e.g., compositions comprising one or more microbes or protein components thereof), that can be administered to subjects to confer beneficial effects. Disclosed compositions can, for example, be useful in reducing visceral hypersensitivity, or pain in response to colorectal distension.

Provided are a 4-ureido-5-carboxyl-imidazole-amide hydrolase and use thereof, particularly use in the treatment of gout.

The presently claimed subject matter concerns methods and kits for identifying agents that reduce binding of a clostridial neurotoxin to synaptic vesicle glycoprotein 2 (SV2).